Grifols S.A. (GRFS) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Grifols S.A. is the larger company by market cap ($5.55 billion vs $5.04 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRFS | MANE |
|---|---|---|
| Share price | $8.15 | $119.52 |
| Market cap | $5.55B | $5.04B |
| 1-day change | -0.61% | -3.92% |
| YTD return | -12.83% | — |
| 1-year return | -2.98% | — |
| 5-year return | -25.30% | — |
| P/E ratio (TTM) | 9.82 | — |
| Forward P/E | 6.55 | — |
| EPS (TTM) | $0.83 | $-3.89 |
| Dividend yield | 1.30% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-70.00M |
| 52-week high | $9.77 | $156.63 |
| 52-week low | $6.96 | $32.00 |
| Distance from 52-week high | -16.58% | -23.69% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +27.24% | +56.74% |
| Average volume | 628.64K | 738.22K |
| Shares outstanding | 258.22M | 42.20M |
| Employees | 25,000 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
GRFS vs MANE FAQ
Which is bigger, Grifols S.A. or Veradermics?
Grifols S.A. (GRFS) is larger, with a market capitalization of $5.55B compared with $5.04B for Veradermics (MANE).
Which pays a higher dividend, Grifols S.A. or Veradermics?
Grifols S.A. pays a dividend yielding 1.30%, while Veradermics does not currently pay a regular dividend.
Are Grifols S.A. and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.